Skip to content
‹ Back to IndustriesHealthcare

Is It Time to Revamp the Drug Development Pipeline?

Keypoints: Pharmaceutical industry is under pressure to increase demand and productivity. Pharma manufacturers are also expected to reduce waste in the drug development pipeline. Translational research is to get an idea to translate in a way to benefit the patient. Commentary: The pharmaceutical industry is undergoing a series of rapid changes. These days, there…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Keypoints:

  • Pharmaceutical industry is under pressure to increase demand and productivity.
  • Pharma manufacturers are also expected to reduce waste in the drug development pipeline.
  • Translational research is to get an idea to translate in a way to benefit the patient.

Commentary:

The pharmaceutical industry is undergoing a series of rapid changes. These days, there is higher demand, increased productivity, a race to get the drugs into consumers’ hands at a record pace, and a push to minimize waste in the process. MarketScale talked to Dr. Gabi Hanna, the CEO of Lamassu Pharma, to give his take on the drug development pipeline and what needs to be updated once the drug hits the market.

Abridged Thoughts:

In a basic and simple way, translational research is to take the idea from research and how to translate it into a tangible way to benefit the patient. This is the translation of knowledge to make a real impact on a patient. That is basically, in a nutshell, what does translational research is for us. 

More Like This Story:

What Can the Pharma Industry Learn from Merck’s New Antiviral?

MarketScale sourced Dr. Kishor M. Wasan, Chief Medical and Scientific Officer at Skymount Medical, for his perspective, pulling from his active research around drug production and AI. Scroll down for his various insights!

What is Behind the “Mergers & Acquisitions” Boom in Healthcare?

As the country continues to open and up and start on that path to recovery there has been a recent boom of healthcare mergers and acquisitions. On this upcoming episode of I Don’t Care, Kevin Stevenson speaks with the Co-Founders and Partners of M&A Healthcare Advisors, a boutique advisor firm whose focus is on the healthcare industry. The group talks about their plans to help small to middle sized businesses with M&As and how they hope to work with companies hands-on.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

The American Hospital Association, West Health and BD will add continuous blood pressure monitoring to surgical care at 10 hospitals, with Vizient measuring results. The pilot tests the workflow around the device: who notices a change, who acts and who hands it off. Whether it spreads depends on cost after startup funding ends.

  • 01A monitor running in two operating rooms can support two different decisions, so device usage counts can say little about whether continuous blood pressure monitoring actually changed surgical care.
  • 02Hospitals evaluating continuous monitoring may already own idle devices; learning why they sit unused, whether training time or an awkward spot in the workflow, points to a different fix than a new purchase order.
  • 03A playbook is expected in roughly a year, aiming to define essential steps while leaving room for smaller or resource-limited hospitals—such as those without 24/7 pharmacy coverage—to adapt workflows locally.

Nov 19, 2026

Four renewal questions that can bring HbA1c closer to the dental chair

Four renewal questions that can bring HbA1c closer to the dental chair

Dr. Deepashree Rajendraprasad, a dentist turned hospital business intelligence developer, gives dental practices four questions for software vendors at contract renewal. They cover HL7 FHIR APIs, health information exchange access, SNODENT terminology and electronic referrals. The standards already exist. The payoff shows up chairside in anticoagulant screening, diabetes-guided periodontal care and bisphosphonate surgical planning.

  • 01Rajendraprasad argues that HbA1c is often already structured in medical systems; getting it to the dental chair starts with what a practice asks its software vendor.
  • 02Two of the five FHIR resources most relevant to dentistry, Patient and Observation, belong to the normative core of FHIR Release 4, where future changes are meant to stay backward compatible.
  • 03At renewal, ask vendors specifics: which FHIR resources they expose, whether they can query the regional HIE, whether they code in SNODENT, and whether they support structured referrals.

Nov 18, 2026

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal emphasizes the need for measured baselines, clinician-led design, and representative data for scaling, noting that pilots often hide key scaling insights.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition and baseline metric will this tool be judged against?

Nov 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512